Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICD

This article was originally published in The Gray Sheet

Executive Summary

shock or not?: Patient's with implantable cardioverter defibrillators might experience a better quality of life due to reduced shocks from a regimen of anti-arrhythmic drugs with beta-blockers, according to an article in the Jan. 11 issue of the Journal of the American Medical Association. The study, funded by St. Jude Medical, finds that patients taking the drug amiodarone with beta-blockers have a reduced chance of experiencing an inappropriate shock, an uncomfortable but not physically harmful occurrence caused by the device's inability to differentiate between non-lethal heart rhythms and lethal arrhythmias. Patients on the amiodarone combo have a 10.3% chance of receiving any type of shock in one year, whereas patients taking beta blockers alone have 38.5% chance, according to the study results...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT023108

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel